Long-term prognostic value of coronary atherosclerosis progression in patients with and without diabetes mellitus

冠状动脉粥样硬化进展对伴有和不伴有糖尿病患者的长期预后价值

阅读:1

Abstract

BACKGROUND: Studies of the long-term prognostic value of coronary atherosclerosis progression in patients with and without diabetes mellitus (DM) via serial coronary computed tomography angiography (CCTA) are limited. This study aimed to explore the long-term prognostic value of coronary atherosclerosis progression in patients with and without DM. METHODS: Patients who had undergone serial CCTA were retrospectively enrolled and categorized into DM and non-DM groups. Coronary atherosclerosis progression was defined as any increase in the coronary artery calcium score (CACS), segment involvement score, or segment stenosis score. Major adverse cardiovascular events (MACE) comprised all-cause mortality, myocardial infarction, and coronary revascularization. RESULTS: One hundred and fifteen DM and 410 non-DM patients were included. The median patient age was 56 (49-63) years, and 355 (67.6%) of them were men. The DM group was associated with a greater increase in CACS. During the median follow-up of 69 months, 114 MACE occurred. The Coronary Artery Disease-Reporting and Data System 4-5 [DM: hazard ratio (HR) =2.32, 95% confidence interval (CI): 1.21-4.47, P=0.012; non-DM: HR =2.03, 95% CI: 1.17-3.55, P=0.012], high-risk plaque (DM: HR =2.85, 95% CI: 1.41-5.76, P=0.004; non-DM: HR =1.99, 95% CI: 1.09-3.65, P=0.026), and atherosclerosis progression (DM: HR =3.15, 95% CI: 1.21-8.19, P=0.019; non-DM: HR =2.40, 95% CI: 1.28-4.50, P=0.006) were significant predictors of MACE in DM and non-DM groups. The event-free survival rate of the DM group with atherosclerosis progression was 49.1%. CONCLUSIONS: Atherosclerosis progression was the strongest predictor of MACE in both DM and non-DM groups. The DM group with atherosclerosis progression had the lowest event-free survival rate.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。